Measles Resurgence Sparks Scientists’ Search For Revolutionary Therapy

As measles cases surge across the United States, scientists are racing to develop the first-ever targeted therapy for the virus, a move that could transform how the disease is treated and controlled. With outbreaks now surpassing levels not seen in decades, researchers at leading institutions are focusing on antibody-based treatments that could neutralize the virus before it causes severe illness, especially in those who cannot be vaccinated.

The resurgence of measles has been striking. Since January 2025, there have been more than 3,500 confirmed cases in 46 states, the largest outbreak since the disease was declared eliminated in the U.S. In 2000. South Carolina has reported nearly 1,000 cases, while Texas and New Mexico have seen measles-related deaths, the first in the U.S. Since 2015. The virus is spreading more widely and silently than ever before, with genetic sequencing and wastewater surveillance revealing chains of transmission that traditional case reporting has missed.

Current treatment for measles is largely supportive, as there is no specific antiviral drug approved for use. But new research is changing that. The Vanderbilt Center for Antibody Therapeutics has entered into an agreement to develop human monoclonal antibodies isolated in the lab of James Crowe Jr., MD, targeting the measles virus. These antibodies bind to viral proteins, potentially stopping the virus from infecting cells and spreading through the body.

Meanwhile, Invivyd, a biotechnology company, has announced progress in its REVOLUTION program, advancing a novel monoclonal antibody candidate called VMS063 for both treatment and prevention of measles. Early data suggest this approach could be the first of its kind, offering a new tool to combat the virus outside of vaccination.

Researchers at the Texas Biomedical Research Institute are also testing what could be the first therapeutic for measles. Their antibody-based therapy aims to halt the virus’s progression in the body, which could be especially beneficial for hospitalized patients or those with weakened immune systems. The potential treatment is still in development, but it represents a major step forward in addressing a disease that has long relied on prevention through vaccination.

Despite these advances, vaccination remains the cornerstone of measles control. Nationally, vaccination rates among school-age children have fallen from 95% in 2019 to 92% in 2023, leaving many communities vulnerable. In some areas, rates have dipped below 95%, the threshold needed for herd immunity. The current outbreaks underscore the importance of maintaining high vaccination coverage, even as new therapies are explored.

While antibody treatments offer hope, they are not yet widely available. Clinical trials are underway, and regulatory approval could take time. In the meantime, public health officials continue to urge vaccination, especially for children, as the most effective way to prevent measles and its potentially deadly complications.

As the scientific community works to bring these new therapies to market, the measles resurgence serves as a reminder of how quickly infectious diseases can re-emerge—and how critical We see to have multiple strategies in place to protect public health.